PL2118309T3 - Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania - Google Patents

Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania

Info

Publication number
PL2118309T3
PL2118309T3 PL07870089T PL07870089T PL2118309T3 PL 2118309 T3 PL2118309 T3 PL 2118309T3 PL 07870089 T PL07870089 T PL 07870089T PL 07870089 T PL07870089 T PL 07870089T PL 2118309 T3 PL2118309 T3 PL 2118309T3
Authority
PL
Poland
Prior art keywords
diagnostic
autoimmune diseases
therapeutic target
therapeutic
target
Prior art date
Application number
PL07870089T
Other languages
English (en)
Polish (pl)
Inventor
John C Hutton
Janet M Wenzlau
Jan Jensen
Howard Davidson
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of PL2118309T3 publication Critical patent/PL2118309T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
PL07870089T 2006-12-29 2007-12-28 Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania PL2118309T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88281506P 2006-12-29 2006-12-29
PCT/US2007/089125 WO2008083331A2 (en) 2006-12-29 2007-12-28 Diagnostic and therapeutic target for autoimmune diseases and uses thereof
EP07870089.5A EP2118309B1 (en) 2006-12-29 2007-12-28 Diagnostic and therapeutic target for autoimmune diseases and uses thereof

Publications (1)

Publication Number Publication Date
PL2118309T3 true PL2118309T3 (pl) 2015-07-31

Family

ID=39589229

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07870089T PL2118309T3 (pl) 2006-12-29 2007-12-28 Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania

Country Status (8)

Country Link
US (1) US9023984B2 (enExample)
EP (1) EP2118309B1 (enExample)
JP (1) JP5694668B2 (enExample)
CN (1) CN101646781B (enExample)
DK (1) DK2118309T3 (enExample)
ES (1) ES2533566T3 (enExample)
PL (1) PL2118309T3 (enExample)
WO (1) WO2008083331A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2486122A (en) * 2009-09-18 2012-06-06 Univ California Methods for detecting autodigestion
CN102060910B (zh) * 2010-11-12 2012-11-21 中国人民解放军第三军医大学 锌转运蛋白8的hla-a＊0201限制性ctl表位及其应用
KR20250020688A (ko) * 2011-04-29 2025-02-11 셀렉타 바이오사이언시즈, 인크. 항체 반응을 감소시키기 위한 관용원성 합성 나노운반체
US20140271701A1 (en) 2011-10-26 2014-09-18 Universita' Degli Studi Di Sassari Use of mycobacterium avium paratuberculosis peptides to diagnose type 1 diabetes
CN103177198B (zh) * 2011-12-26 2016-11-23 深圳华大基因科技服务有限公司 一种蛋白质鉴定方法
IN2014DN09410A (enExample) 2012-04-13 2015-07-17 Diabetomics Llc
CN102967704B (zh) * 2012-11-26 2014-05-14 深圳市伯劳特生物制品有限公司 一种用于糖尿病自身抗体6项联检试剂盒
US20160025744A1 (en) * 2013-03-14 2016-01-28 The Board Of Trustees Of The Leland Stanford Junior University Plasmonic substrate for multiplex assessment of type 1 diabetes
MX2021005697A (es) 2013-05-03 2021-07-07 Selecta Biosciences Inc Suministro de inmunosupresores que tienen una vida efectiva especificada, farmacodinamica y antigeno para la induccion de tolerancia inmunitaria.
KR102523912B1 (ko) 2013-06-11 2023-04-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
CN106535926B (zh) * 2014-06-04 2022-02-01 戴尔米德医疗公司 用于基于抗原的疗法的新型组合物
KR101482908B1 (ko) 2014-07-25 2015-01-15 충남대학교산학협력단 간질중첩증 진단용 바이오마커 조성물
CN106714826A (zh) 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
EP4374863A3 (en) 2014-12-18 2024-09-04 President and Fellows of Harvard College Methods for generating stem cell-derived beta cells and uses thereof
CN113234661A (zh) 2014-12-18 2021-08-10 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
GB201510056D0 (en) * 2015-06-10 2015-07-22 King S College London Multi-peptide composition
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
US20170082619A1 (en) 2015-09-23 2017-03-23 One Lambda, Inc. Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens
CN106084051B (zh) * 2016-02-17 2018-03-02 张梅 一种ZnT8特异性单链抗体scFv‑C27及其应用
CN106084043B (zh) * 2016-02-17 2018-03-02 张梅 一种ZnT8特异性单链抗体scFv‑C22及其应用
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
CN106771233A (zh) * 2016-12-05 2017-05-31 上海良润生物医药科技有限公司 ZnT8A自身抗体检测试剂盒
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
MX2020004939A (es) 2017-11-15 2020-11-11 Semma Therapeutics Inc Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.
CN108414766A (zh) * 2018-01-29 2018-08-17 上海良润生物医药科技有限公司 用于定量检测糖尿病自身抗体的试剂盒及其应用
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
EP3837286A4 (en) 2018-08-16 2022-08-10 The Johns Hopkins University ANTIBODIES TO HUMAN ZNT8
CN109628462B (zh) * 2018-12-13 2021-02-19 宁波大学 一种水稻根系伸长控制基因OsKSR7及编码的蛋白质
CN109734793B (zh) * 2019-03-14 2022-12-02 深圳市药品检验研究院（深圳市医疗器械检测中心） 一种ZnT8重组蛋白及其制备方法和应用
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
CN111579791A (zh) * 2020-04-30 2020-08-25 江苏省人民医院（南京医科大学第一附属医院） 一种锌转运体8胰岛自身抗体的电化学发光检测试剂盒
CN113999841A (zh) * 2021-09-16 2022-02-01 江苏省人民医院（南京医科大学第一附属医院） 蛋白质支架oval100及其在放射配体法中的应用
CN116589589B (zh) * 2023-03-24 2024-10-22 深圳市昭蓝生物科技有限公司 糖尿病检测的质控品及其制备方法和用途
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒
CN120714599B (zh) * 2025-08-28 2025-10-31 江苏集萃医工交叉技术研究所有限公司 一种血清bicc1天然蛋白的高效提取保存方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US20020082207A1 (en) 2000-06-07 2002-06-27 Hirst Shannon K. Compositions and methods for the therapy and diagnosis of pancreatic cancer
FR2847263B1 (fr) 2002-11-18 2006-01-13 Commissariat Energie Atomique Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans

Also Published As

Publication number Publication date
ES2533566T3 (es) 2015-04-13
EP2118309B1 (en) 2015-01-28
US9023984B2 (en) 2015-05-05
JP5694668B2 (ja) 2015-04-01
DK2118309T3 (en) 2015-03-30
JP2010514805A (ja) 2010-05-06
WO2008083331A2 (en) 2008-07-10
EP2118309A4 (en) 2010-06-02
CN101646781B (zh) 2016-06-22
WO2008083331A3 (en) 2008-11-13
CN101646781A (zh) 2010-02-10
US20100143374A1 (en) 2010-06-10
EP2118309A2 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
PL2118309T3 (pl) Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania
IL195052A0 (en) Patient customized therapeutic regimens
EP2076198A4 (en) Inducing Desired Temperatreating Effects on Body Weave
EP2119444A4 (en) THERAPEUTIC AGENT FOR PAIN
GB0625659D0 (en) Therapeutic compounds and their use
SI2056842T1 (sl) Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
EP2076194A4 (en) SYSTEM FOR GENERATING DESIRED TEMPERATURE EFFECTS ON BODY TISSUE
GB0602178D0 (en) Therapeutic treatment
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
EP2026738A4 (en) PATIENT AUSCULTATION SYSTEM
IL193604A (en) Use of human anti-22 @ il antibodies for @ preparation
WO2010141469A9 (en) Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases
GB0722996D0 (en) Depsipeptides and their therapeutic use
IL192415A0 (en) Pharmaceutical composition for the treatment of nail diseases
GB2457640B (en) Body armour
IL212800A0 (en) N-cadherin: target for cancer diagnosis and therapy
GB0608655D0 (en) Therapeutic Treatment
EP1976426A4 (en) SYSTEM AND METHODS FOR MEDICAL DIAGNOSIS
GB0700645D0 (en) Targets for disease therapy
GB0610909D0 (en) Therapeutic treatment
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
GB0621308D0 (en) An implement for administering medicine
GB0605738D0 (en) Novel diagnostic and therapeutic methods
HK1127144A (en) Patient customized therapeutic regimens
GB0610376D0 (en) Therapeutic treatment